Lenders line up more than 10 billion euros for Sanofi health unit buyout

New York-based buyout company Clayton Dubilier & Rice is competing with French rival PAI Partners for Sanofi’s unit, with bids due this month

    • The financing of Sanofi bids has drawn as many as 15 banks, as they compete to return to funding leveraged buyouts, especially after the US Federal Reserve's recent rate cut.
    • The financing of Sanofi bids has drawn as many as 15 banks, as they compete to return to funding leveraged buyouts, especially after the US Federal Reserve's recent rate cut. PHOTO: REUTERS
    Published Tue, Sep 24, 2024 · 08:44 PM

    BANKS and other lenders are lining up more than 10 billion euros (S$14.3 billion) of debt to back a buyout of Sanofi’s consumer health division, as one of the most highly anticipated sales of the year reaches its final stages.

    A core group of banks signed funding commitments over the weekend for 7.5 billion to 7.8 billion euros of senior debt to back bids for the acquisition, sources said, declining to be identified discussing private matters.

    They will also give around 1.2 billion euros of revolving credit facility.

    Private credit lenders are also lining up around 1.5 billion to two billion euros of junior debt to fund the buyout.

    New York-based buyout company Clayton Dubilier & Rice (CD&R) and its French rival PAI Partners are vying to buy Sanofi’s unit. Bids are due this month.

    CD&R is being advised by Citigroup, and PAI Partners, by JPMorgan Chase.

    BT in your inbox

    Start and end each day with the latest news stories and analyses delivered straight to your inbox.

    The debt packages backing both bids are fairly similar, and include a mix of euro and dollar-denominated leveraged loans, and high-yield bonds to attract as much liquidity from institutional investors as possible, they added.

    While Sanofi did not comment on the financing, a representative reiterated that the company is considering potential separation scenarios for the consumer business, including a sale or a stock market listing, with a decision likely in the next few months.

    Spokespersons for CD&R, PAI, JPMorgan and Citi declined to comment. 

    Banks are eager to return to funding leveraged buyouts, with as many as 15 jostling for the financing on the Sanofi bids.

    Such deals are some of the most lucrative operations in finance, particularly after the first US Federal Reserve interest rate cut in four years raised hopes that debt costs are finally starting to ease.  

    But the risks are still fresh on many people’s memories: Just two years ago, lenders got burned backing big corporate buyouts and ended up with tens of billions of dollars of “hung debt” they struggled to get rid of. 

    The total leverage provided by banks will likely be six times the unit’s earnings, a level that is fairly high by recent standards.

    That figure rises to 7.5 times once the private credit element is factored in. Only slightly more than a year ago, the debt packages lined up by banks to back buyouts were around four times earnings.

    Bloomberg News previously reported that New York-based buyout firm CD&R is also in discussions with banks to provide back leverage to fund part of the equity cheque.

    Back leverage is a type of loan that buyout shops can obtain to finance part of an equity investment in a specific company. BLOOMBERG

    Share with us your feedback on BT's products and services